Pictet Asset Management Holding SA Sells 78,783 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Pictet Asset Management Holding SA cut its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 4.9% in the 4th quarter, HoldingsChannel reports. The fund owned 1,540,485 shares of the biopharmaceutical company’s stock after selling 78,783 shares during the period. Pictet Asset Management Holding SA’s holdings in Intra-Cellular Therapies were worth $128,661,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in ITCI. True Wealth Design LLC bought a new stake in Intra-Cellular Therapies during the 3rd quarter worth approximately $32,000. GAMMA Investing LLC boosted its position in shares of Intra-Cellular Therapies by 46.3% during the fourth quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock valued at $63,000 after buying an additional 240 shares during the last quarter. Venturi Wealth Management LLC bought a new stake in Intra-Cellular Therapies during the fourth quarter worth $96,000. Wilmington Savings Fund Society FSB purchased a new stake in Intra-Cellular Therapies in the 3rd quarter valued at $97,000. Finally, Quarry LP lifted its stake in Intra-Cellular Therapies by 260.0% during the 3rd quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company’s stock valued at $132,000 after acquiring an additional 1,300 shares in the last quarter. Institutional investors and hedge funds own 92.33% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on ITCI shares. Mizuho lowered shares of Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and dropped their price target for the company from $140.00 to $132.00 in a research report on Monday, February 24th. Piper Sandler reissued a “neutral” rating and set a $132.00 target price (up previously from $107.00) on shares of Intra-Cellular Therapies in a research report on Tuesday, January 14th. Cantor Fitzgerald raised Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 14th. Baird R W lowered Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Finally, StockNews.com initiated coverage on Intra-Cellular Therapies in a research note on Friday. They issued a “hold” rating for the company. Ten analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Intra-Cellular Therapies currently has an average rating of “Hold” and a consensus price target of $106.08.

Intra-Cellular Therapies Stock Up 0.0 %

NASDAQ ITCI opened at $131.81 on Friday. The company has a market cap of $14.04 billion, a PE ratio of -151.50 and a beta of 0.69. The firm’s 50-day simple moving average is $129.12 and its two-hundred day simple moving average is $99.45. Intra-Cellular Therapies, Inc. has a 52 week low of $64.09 and a 52 week high of $131.87.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The business had revenue of $199.22 million during the quarter, compared to the consensus estimate of $205.08 million. As a group, equities research analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current year.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.